Dr. Chau on CheckMate577 Study in Esophageal/GEJ Cancer

Ian Chau, MD, consultant medical oncologist, Royal Marsden Hospital, discusses the CheckMate 577 study in resected lower esophageal or gastroesophageal junction (GEJ) cancer.

CheckMate 577 is a randomized, double-blind, phase III study of nivolumab (Opdivo) in the adjuvant setting. Patients with stage I/II esophageal or GEJ cancer that have undergone preoperative chemoradiotherapy (CRT) are randomized to receive either nivolumab or placebo. This is due to the increase in expression of PD-L1 after CRT, says Chau, which has demonstrated survival benefits when combined with nivolumab.

This study is ongoing, with primary endpoints of overall survival and disease-free survival.